Press Esc to close

Welcome to Money Morning - Only the News You Can Profit From.

Close

This Says Our Favorite Biotech Is Off to the Races

Shares of a promising biotech we recommended back in February 2013 – jumped as much as 27% to a three-month high of $14.20 yesterday after the company said a new cancer drug met its main goal in a midstage clinical trial.

Its shares backtracked a bit as the day progressed but still closed 17.6% higher for the session. These shares have advanced 361% since we first told you about them. The stock has generated a peak gain of 456%, making it one of the 31 recommendations we’ve made to you that have doubled or better since we launched Private Briefing in August 2011. (More on that later…)

Your Advisors

Keith Fitz-Gerald- Money Morning - Only the News You Can Profit From.

Keith is a seasoned market analyst with decades of experience, known and admired for his perspectives and insights, as well as a highly accurate track record of both predictions and trades.

At just 15, he started his first business and used the proceeds to make his first investment. He then cut his teeth working for one of the world's leading investment powerhouses, before becoming a professional trader and licensed CTA, advising institutions and qualified individuals, and specializing in non-directional trading.

Today Keith is a regular guest on Fox Business, CNBC Asia, and BNN. He's also a bestselling author. His book, "Fiscal Hangover: How to Profit from the New Global Economy" (John Wiley & Sons), continues to garner rave reviews.

Keith has been leading The Money Map Report as Chief Investment Strategist since 2008. He's also the editor of The Geiger Index, an ultra-reliable, emotion-free guide to making big money and avoiding losses. (The Geiger is on a serious roll, with a near-perfect track record over five years.) His Strike Force publication has a very straightforward strategy: Get in, target gains of at least 100%, and get out clean. 

Keith holds a BS in management and finance from Skidmore College and an MS in international finance (with a focus on Japanese business science) from Chaminade University. He splits his time between the United States and Japan, and regularly travels the world in search of investment opportunities others don't yet see or understand.